gastroAI model-G3

Organization
AI Medical Service Inc. (AIM) · Japan
Solution Type
Ready Product / Solution
Collaboration
Business Collaboration (Joint Venture), Licensing
gastroAI model-G3

1. Technology overview

AI Medical Service Inc. (AIM) was founded on September 1, 2017 and is headquartered in Tokyo, Japan, with a branch in Singapore and offices in the United States. The company develops endoscopic AI with the mission of reducing gastrointestinal cancer deaths by catching cancers that endoscopy might otherwise miss.

gastroAI model-G3 supports lesion detection during upper GI endoscopy. It analyzes endoscopic video in real time, flags areas that may be early gastric cancer or adenoma with up to three markers, uses multi-frame analysis to limit false positives, and pauses automatically when images are unsuitable. It is positioned as an examiner's aid, not a diagnostic decision tool.

2. Highlighted features & specifications

  • Real-time video analysis: Analyzes endoscopic video during upper GI examination.
  • Lesion markers: Overlays up to three markers on regions that may be early gastric cancer or adenoma.
  • Multi-frame analysis: Aims for high detection while reducing false positives.
  • Image quality check: Automatically detects unsuitable images and pauses analysis.
  • Examiner aid design: Supports detection only, leaving diagnosis and treatment decisions to physicians.
  • Regulatory coverage: Approved in Japan in May 2026 and in Thailand in 2025.

3. Potential application

Endoscopy departments of large Vietnamese hospitals can use real-time lesion flagging as a second reader during upper GI screening. Health-check centers can use it to standardize detection quality across less experienced endoscopists.

4. Benefits

Assists endoscopists in spotting early gastric cancer and adenoma during live examination. Retrospective study on 1,099 samples reported sensitivity of 94.6% and specificity of 94.3% (company-reported). Multi-frame analysis aims to keep false positives low. Approved as a medical device in Japan, with Thailand approval in 2025.

6. Other information

Founded September 1, 2017, Tokyo; Singapore branch and US offices; about 100 employees (September 2025); capital of 13.8 billion yen including reserves. Thailand FDA approval in 2025; Japan approval in May 2026.

AI Medical Service Inc. (AIM)
View organization profile

Not ready to connect yet?

Save this solution and come back when you are ready to talk to the provider

Trusted by Our Partners

TechFest VietnamIOM – UN MigrationGIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)APED – Cục Phát triển doanh nghiệp tư nhân và kinh tế tập thểSIHUB – Startup and Innovation Hub of Ho Chi Minh CityHợp tác Đức (Deutsche Zusammenarbeit)SCE & Investment PromotionStartup Vietnam Foundation (SVF)National Startup Support Center (NSSC)01BoosterQuest VenturesBộ Tài chính (Ministry of Finance)ITPC – HCMC Investment and Trade Promotion CentreJICA – Japan International Cooperation AgencyNational Innovation Center (NIC)UK GovernmentBCG – Boston Consulting GroupHAWEEHeineken VietnamTalentnetMB BankVIREA – Liên chi hội Bất động sản Công nghiệp Việt NamJobTestGlobal Supply Chain Support Fund / Aavishkaar CapitalKDANPSE / JPS – Phúc Sang MinhG-AsiaPacificBlueScopeLPBankUlsan Center for Creative Economy & InnovationĐại học Bách khoa Hà Nội – Trường Điện - Điện tửVINK – Vietnam Innovation Network in KoreaTencent WeStart (Shenzhen)Ulsan CollegeK-StartupFaslinkShinhan Future's LabShinhan SecuritiesShinhan FinanceShinhan BankShinhan Life

Start with the right connection

We make innovation easy to access for every business everywhere. The next deal is you.

Contact Us